Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

3 Months Ended

Mar. 31, 2015

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

4. Accrued Expenses

Accrued expenses consist of the following:

		March 31,
		2015			December
		(Unaudited)			31, 2014
Payroll and benefits		$	36,301		$	168,269
Clinical trials			55,054			57,629
Consulting			13,916			8,917
Professional fees			21,241			534,984
Accrued interest			0			143,264
Total accrued expenses		$	126,512		$	913,063